Clinical Trial Update: Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

Open-label Phase 2/3 trial of ATH-1017 for mild to moderate Alzheimer's disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ATH-1017

Snippet

Sponsor: LeonaBio | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-04-01